Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (48 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2026-08-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: heartfailureventricularfractionejection
  Phrases that lowered it: kneearthritisparticipantparticipantssingle
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 14.4% (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 54.8% (lowers risk) · Drug's FDA history
• Collaborators: 3 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 186 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Phase: 2/3 (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past trials: 1045 (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Drug's FAERS reports with a death: 2.4% (lowers risk) · Drug's FDA history
• Responsible party: principal investigator (lowers risk) · Design
• Number of arms: 2 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Effects of Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF) NCT03833336 · started 2017 · scored riskier than 90% of active trials completed
• Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency NCT03218384 · started 2017 · scored riskier than 58% of active trials terminated
• Oral Iron Repletion Effects On Oxygen Uptake in Heart Failure NCT02188784 · started 2014 · scored riskier than 99% of active trials completed
• Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study NCT03037931 · started 2017 · scored riskier than 98% of active trials completed
• Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF) NCT02840799 · started 2016 · scored riskier than 40% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.